DIHYDROERGOTAMINE MESYLATE

Post-LOE

dihydroergotamine mesylate

Baxter

ANDAINJECTIONINJECTABLE

Approved

Jan 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DIHYDROERGOTAMINE MESYLATE (dihydroergotamine mesylate) by Baxter is mechanism of action dihydroergotamine binds with high affinity to 5-ht 1d α and 5-ht 1d β receptors. Approved for migraine. First approved in 2020.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1D α and 5-HT 1D β receptors. It also binds with high affinity to serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, noradrenaline α 2A , α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The therapeutic activity of…

Indications (1)

migraine

Clinical Trials (1)

NCT01089062Phase 1Completed

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Started Mar 2010

24 enrolled

Healthy

Worked on DIHYDROERGOTAMINE MESYLATE at Baxter? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.